Frabex 500
230.00৳ Strip
- Tranexamic Acid: Potent antifibrinolytic medication used across medical specialties.
- Mechanism: Inhibits plasminogen activation, promoting clot formation and reducing bleeding.
- Low Toxicity: Minimal acute and chronic effects, well-absorbed orally, mainly excreted via the renal route.
- Versatile Application: Effective in managing hemorrhagic conditions in medicine, surgery, urology, obstetrics, etc.
- Valuable Tool: Provides lasting antifibrinolytic activity, aiding in bleeding disorder management and surgical procedures.
Brand |
Square Pharmaceuticals PLC |
---|---|
Generics |
Tranexamic Acid |
Indications
In the medical field, Tranexamic Acid is used for both prophylaxis and therapy in various conditions such as hemoptysis, digestive hemorrhages, hemorrhagic syndromes associated with leukemia, cirrhosis, and hemophilia, thrombocytopenic purpura, accidents during thrombolytic therapy and transfusion. In surgical procedures, it is utilized for prophylaxis and antihemorrhagic therapy across different types of operations, particularly in pulmonary, cardiovascular, and abdominal surgeries, as well as in post-operative and traumatic shock. In urology, it is employed for the prophylaxis and antihemorrhagic therapy of prostatic, vesical, and renal surgeries, and for hematuria. In obstetrics, Tranexamic Acid is indicated for the prevention and treatment of post-partum and puerperium hemorrhages, hemorrhagic metropathies, functional menometrorrhagias, idiopathic or IUD (Intrauterine Device) induced menorrhagias, primitive hyperfibrinolysis (e.g., abruptio placentae, premature placenta detachment), and in cervical conization. In otorhinolaryngology, it is used for prophylaxis and antihemorrhagic therapy during tonsillectomy, other specialist surgeries, and in cases of epistaxis. In stomatology, it serves for prophylaxis and antihemorrhagic therapy during maxillofacial operations and tooth extractions. Additionally, in oncology, Tranexamic Acid is employed as supportive therapy to promote the formation of a fibrin capsule to inhibit the growth of ovarian tumors, cause regression of ascites secondary to carcinoma, and reduce bleeding during surgical interventions.
Pharmacology
Tranexamic Acid, also known as trans-4 aminomethyl-cyclohexanecarboxylic acid, exhibits potent antifibrinolytic action both in vivo and in vitro, proving to be 10 times more active than conventional hemostatics. Its antihemorrhagic action is primarily attributed to the inhibition of plasminogen activation, including both exogenous activators like streptokinase and endogenous ones like urokinase and the plasminogen tissue activator. This mechanism ensures antifibrinolytic activity under various conditions. The acute toxicity of Tranexamic Acid is extremely low, and chronic toxicity is almost non-existent. It is well absorbed orally, with effects seen within 15-30 minutes after administration. Excretion occurs mainly via the renal route, contributing to its lasting effect compared to conventional hemostatics. Tranexamic Acid does not interfere with clotting processes at therapeutic doses, nor does it induce thrombophilia, even with prolonged administration.
Dosage & Administration
For adults, the usual dose ranges from 500-1000 mg three times daily. Prophylactic doses typically range from 0.5-1 gm orally or 500 mg parenterally (intravenously or intramuscularly) daily. In cases requiring therapy for hemorrhagic manifestations, the oral dose may increase to 1-3 gm administered in divided doses, with initial intravenous administration for urgent cases followed by oral doses. For children, prophylactic doses are calculated based on body weight, while therapeutic doses are double the oral prophylactic doses. Intravenous and intramuscular treatments are initiated with 10 mg/kg, with subsequent oral administration.
Elderly patients generally do not require dosage reduction unless renal failure is evident.
*Advice from a physician should be sought before medication administration.
Interaction
Tranexamic Acid may be incompatible with solutions containing penicillins (e.g., Benzyl penicillin). Thrombolytic drugs such as Streptokinase & Urokinase may antagonize its antifibrinolytic action. The potential for thrombus formation may increase with concomitant administration of estrogen-containing drugs, like oral contraceptives. Direct admixture with whole blood during transfusion should be avoided.
Contraindications
Tranexamic Acid is contraindicated in individuals with known hypersensitivity to the product, thromboembolic disease, arterial and venous thrombosis, endocavitary hemorrhages, and serious kidney failure.
Side Effects
Common side effects include fatigue, conjunctival irritation, nasal blockage, itching, skin reddening, and rashes. Gastrointestinal effects such as nausea, diarrhea, and gastric pyrosis may occur after oral administration. Postural hypotension is rare. In cases of hypersensitivity, treatment should be avoided or suspended, and suitable therapy initiated.
Pregnancy & Lactation
Tranexamic Acid should not be administered during known or presumed pregnancy due to unknown effects on the fetus. It passes into breast milk in minimal concentrations unlikely to exert antifibrinolytic effects in infants.
Precautions & Warnings
Tranexamic Acid should be used cautiously in hyperfibrinolysis cases. Prophylactic treatment should commence 24 hours before surgery and continue for 3-4 days post-surgery. Hemorrhage therapy should be prolonged for at least 24 hours after symptoms subside. In hematuria cases, doses should be reduced to prevent clot formation in the urinary tract. It should be used with caution in serious renal insufficiency or anuric syndromes and particular care in individuals with cardiac or hepatic conditions.
Therapeutic Class
Tranexamic Acid falls under the category of anti-fibrinolytic drugs and haemostatic agents.
Storage Conditions
Store in a dry place at temperatures between 15-30°C, away from light, and out of children’s reach.
Reviews
There are no reviews yet.